| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.17 | 0.001 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.099 | 0.002 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.002 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.002 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.12 | 0.003 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.12 | 0.003 |